Results 91 to 100 of about 149,152 (218)

Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria

British Journal of Clinical Pharmacology, EarlyView.
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova, Yoana Lilova, Alexander Oscar, Alina Levi, Maria Kamusheva, Guenka Petrova   +5 more
wiley   +1 more source

GP perspectives on genomics in primary care: a qualitative study on using polygenic risk scores to evaluate cancer risk. [PDF]

Br J Gen Pract
Ramsay G, Brooks R, Wade C, Liew JJM, Alphonse P, McIntosh J, Forrest LE, Emery J, Saya S.   +8 more
europepmc   +1 more source

SYSTEMIC CREDIT RISK IN THE PRESENCE OF CONCENTRATION [PDF]

In a Black-Scholes-Merton model of single name default, instability could be seen as the level of volatility that would trigger default, everything else equal.
Galizia, Federico
core  

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

British Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang, Chen‐Han Chueh, Chien‐Yu Tseng, Christopher N. Kaufmann, Earl J. Morris, Chiao‐En Wu, Yi‐Wen Tsai   +6 more
wiley   +1 more source

Refractive Outcomes of Cataract Surgery Using Zeiss Artificial Intelligence Calculator versus Barrett Universal II and Kane. [PDF]

Clin Ophthalmol
Cannon NT, Redden L, Riaz KM, Scruggs K, Pantanelli SM.   +4 more
europepmc   +1 more source

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

British Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić, Ivana Stević, Elvira Meni Maria Gkrinia, Dinko Vitezić, Slobodan Janković   +4 more
wiley   +1 more source

High-Cost Healthcare Technology Versus Employment Generation: Equity, Evidence, and Influence in Developing Health Systems. [PDF]

Cureus
Karim HMR.
europepmc   +1 more source

Would a Flat Tax Stimulate Entrepreneurship in Germany?: A Behavioural Microsimulation Analysis Allowing for Risk [PDF]

When possible income tax reforms are debated, the suspected impact on entrepreneurship is often used as an argument in favour or against a certain policy.
Frank M. Fossen
core  

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Financial Burden in Adults With Chronic Illness in Switzerland: A Secondary Analysis of Qualitative Interviews Using Natural Language Processing and Topic Modeling. [PDF]

JMIR Form Res
Spitale G, Seinsche J, Visscher RMS, Schöpf-Lazzarino A, Jurisic J, Germani F, Alder E, Biller Andorno N, Ribi K, Schwind B.   +9 more
europepmc   +1 more source